Pluristem CEO: Little chance of failure
Linkedin

Pluristem CEO: Little chance of failure

Dax : France | Oct 09, 2012 at 10:49 AM PDT
Source: Globes Online
XX XX
Views: Pending
 
Pluristem, which is developing placental stem cells for a range of therapies, is a pioneer in its field...To date, the company's products have undergone a single study with 27 patients, and with no control group...Since announcing the results of the clinical trial, Pluristem has raised $75 million... FULL ARTICLE AT Globes Online
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
  • Credibility
  • Wait... Flag
 
 
Advertisement
 

More From Allvoices

Most Commented Reports



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.